Uquifa is the API division of Vivimed Labs. Uquifa is a manufacturer of Active Pharmaceutical Ingredients (APIs) and intermediates for the pharmaceutical Industry. Operates 3 manufacturing sites, 2 in Spain and 1 in Mexico, which operates under cGMP conditions and has been inspected and approved by major Pharmaceutical Companies and Regulatory Authorities, including the US FDA.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MedTech

COSMOSID LAUNCHES ACCURATE AND EASY FUNCTIONAL MICROBIOME ANALYSIS WITH NEW SOFTWARE PLATFORM, COSMOSID-HUB: MICROBIOME

CosmosID | September 27, 2021

news image

A complete analysis of the microbiome should combine taxonomic profiling ("who is there?") with functional characterization ("what are they doing?") to discover the capabilities of an entire community of microorganisms. But research teams often require specialized training and extensive computational infrastructure to establish an in-house suite of tools for processing shotgun metagenomic data – and even with the right know-how, the processing can be both time-consuming...

Read More

CYTODYN ANNOUNCES FIRST SITE IN THE SOUTHEASTERN USA TO ENROLL PATIENTS IN PHASE 2 CORONAVIRUS TRIAL

Proactive Investors | April 08, 2020

news image

The Novant Health network cares for around 5 million patients a year at nearly 700 locations, including 15 hospitals and hundreds of outpatient facilities and physician clinics. CytoDyn Inc (OTCQB:CYDY), the late stage biotech, said partner Novant Health has started enrolling patients in the company's Phase 2 randomized clinical trial using leronlimab for coronavirus (COVID-19) patients with mild-to-moderate symptoms. Novant Health is the second trial site in the USA and the first site in th...

Read More

Medical

SOSEI HEPTARES' COVID-19 PROGRAM IDENTIFIES POTENT BROAD SPECTRUM ANTI-VIRAL SMALL MOLECULES FOR FURTHER DEVELOPMENT

Sosei Heptares | November 21, 2020

news image

Sosei Group Corporation ("the Company") (TSE: 4565) announces a progress update for its R&D program focused on the design and development of novel drugs targeting the SARS-CoV-2 coronavirus and to treat COVID-19.The program was initiated in April 2020. To date, the Company has applied its world-leading structure-based drug design (SBDD) capabilities and cutting-edge technologies to precision-design new inhibitors of the SARS-CoV-2 Mpro protease, which plays a crucial role in ...

Read More

Medical

BLUEROCK THERAPEUTICS AND BIT.BIO ANNOUNCE COLLABORATION AND OPTION AGREEMENT FOR THE DISCOVERY AND MANUFACTURE

PRNewswire | August 04, 2023

news image

BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned, independently operated subsidiary of Bayer AG, and bit.bio, the company coding human cells for novel cures, today announced a collaboration and option agreement for the discovery and manufacture of iPSC-derived regulatory T cells (Tregs) for use in creating therapeutics. "Tregs play a crucial role in maintaining balance in the body's immune system and controlling excessive immune reactions...

Read More
news image

MedTech

COSMOSID LAUNCHES ACCURATE AND EASY FUNCTIONAL MICROBIOME ANALYSIS WITH NEW SOFTWARE PLATFORM, COSMOSID-HUB: MICROBIOME

CosmosID | September 27, 2021

A complete analysis of the microbiome should combine taxonomic profiling ("who is there?") with functional characterization ("what are they doing?") to discover the capabilities of an entire community of microorganisms. But research teams often require specialized training and extensive computational infrastructure to establish an in-house suite of tools for processing shotgun metagenomic data – and even with the right know-how, the processing can be both time-consuming...

Read More
news image

CYTODYN ANNOUNCES FIRST SITE IN THE SOUTHEASTERN USA TO ENROLL PATIENTS IN PHASE 2 CORONAVIRUS TRIAL

Proactive Investors | April 08, 2020

The Novant Health network cares for around 5 million patients a year at nearly 700 locations, including 15 hospitals and hundreds of outpatient facilities and physician clinics. CytoDyn Inc (OTCQB:CYDY), the late stage biotech, said partner Novant Health has started enrolling patients in the company's Phase 2 randomized clinical trial using leronlimab for coronavirus (COVID-19) patients with mild-to-moderate symptoms. Novant Health is the second trial site in the USA and the first site in th...

Read More
news image

Medical

SOSEI HEPTARES' COVID-19 PROGRAM IDENTIFIES POTENT BROAD SPECTRUM ANTI-VIRAL SMALL MOLECULES FOR FURTHER DEVELOPMENT

Sosei Heptares | November 21, 2020

Sosei Group Corporation ("the Company") (TSE: 4565) announces a progress update for its R&D program focused on the design and development of novel drugs targeting the SARS-CoV-2 coronavirus and to treat COVID-19.The program was initiated in April 2020. To date, the Company has applied its world-leading structure-based drug design (SBDD) capabilities and cutting-edge technologies to precision-design new inhibitors of the SARS-CoV-2 Mpro protease, which plays a crucial role in ...

Read More
news image

Medical

BLUEROCK THERAPEUTICS AND BIT.BIO ANNOUNCE COLLABORATION AND OPTION AGREEMENT FOR THE DISCOVERY AND MANUFACTURE

PRNewswire | August 04, 2023

BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned, independently operated subsidiary of Bayer AG, and bit.bio, the company coding human cells for novel cures, today announced a collaboration and option agreement for the discovery and manufacture of iPSC-derived regulatory T cells (Tregs) for use in creating therapeutics. "Tregs play a crucial role in maintaining balance in the body's immune system and controlling excessive immune reactions...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us